WELCOME TO KARIS BIO차세대 세포치료제 선도기업

Innovative Cell Therapy for Disease
https://karisbio.com/wp-content/uploads/2020/06/home_hero_detail-1.jpg

Our Technology

Cell-Based Therapy

Cell-Based Therapy

Innovative cell-based therapy for treating patients with cardiovascular diseases using patented iPSC differentiation technology.
Growing New Blood Vessels

Growing New Blood Vessels

Human Induced pluripotent stem cell-derived endothelial cells for growing new blood vessels (Neovascularization).
Clinical Trial

Clinical Trial

Peripheral artery disease, myocardial ischemia, ischemic heart failure, diabetic neuropathy, intractable wound, bedsore or pressure ulcer.

Over 20 Years of Experience.

We aims to develop cell-based therapy for treating patients with cardiovascular diseases using patented clinical applicable iPSC generation and endothelial cell differentiation technology.

Human induced pluripotent stem cells (hiPSCs) are developed as a therapeutic agent for treating patients with cardiovascular disease. The first disease target indication is peripheral arterial disease (PAD), which affects 8 – 1.2 million people in the US, typically over the age of 55 years, and results in chronic pain and ulceration. Critical limb ischemia (CLI) is the second target disease indication for this therapy. CLI affects 800,000 to 1 million patients in the US. Up to half of CLI patients undergo amputations within one year. Other potential diseases that would benefit from blood vessel growth or vasculogenesis include ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing.

Innovative Cell Therapy for Cardiovascular Disease